Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
EQ 
Equillium Inc (EQ)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: EQ (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $1
1 Year Target Price $1
| 0 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 31.72% | Avg. Invested days 28 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 35.01M USD | Price to earnings Ratio - | 1Y Target Price 1 |
Price to earnings Ratio - | 1Y Target Price 1 | ||
Volume (30-day avg) 2 | Beta 1.15 | 52 Weeks Range 0.27 - 1.50 | Updated Date 08/15/2025 |
52 Weeks Range 0.27 - 1.50 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.39 |
Earnings Date
Report Date 2025-08-14 | When - | Estimate -0.185 | Actual - |
Profitability
Profit Margin -46% | Operating Margin (TTM) -47.19% |
Management Effectiveness
Return on Assets (TTM) -29.73% | Return on Equity (TTM) -88.32% |
Valuation
Trailing PE - | Forward PE 1.53 | Enterprise Value 19011964 | Price to Sales(TTM) 1.15 |
Enterprise Value 19011964 | Price to Sales(TTM) 1.15 | ||
Enterprise Value to Revenue 0.63 | Enterprise Value to EBITDA 0.07 | Shares Outstanding 35719300 | Shares Floating 18292219 |
Shares Outstanding 35719300 | Shares Floating 18292219 | ||
Percent Insiders 35.9 | Percent Institutions 19.08 |
Upturn AI SWOT
Equillium Inc
Company Overview
History and Background
Equillium, Inc. is a clinical-stage biotechnology company founded in 2017 and headquartered in La Jolla, California. It focuses on developing novel therapeutics to treat severe autoimmune and inflammatory diseases.
Core Business Areas
- Immunomodulatory Therapies: Equillium focuses on developing therapies that modulate immune cell activity to treat autoimmune and inflammatory diseases. Their lead candidate, itolizumab, targets the CD6 receptor on T cells.
Leadership and Structure
Bruce Steel is the CEO. The company has a typical structure for a biotech, with departments focused on research, clinical development, regulatory affairs, and commercialization.
Top Products and Market Share
Key Offerings
- Itolizumab (EQ001): Itolizumab is Equillium's lead product candidate, a monoclonal antibody that targets the CD6 receptor. It is being developed for several indications, including acute graft-versus-host disease (aGVHD) and lupus nephritis. Market share is currently 0 as it's in clinical stages. Competitors include established immunosuppressants and other biologics from companies like Novartis, Roche, and Bristol Myers Squibb for similar indications.
Market Dynamics
Industry Overview
The autoimmune and inflammatory disease market is large and growing, driven by increasing prevalence of these conditions and the development of novel therapies. There is a high unmet need for more effective and safer treatments.
Positioning
Equillium is positioned as a company developing targeted immunomodulatory therapies with the potential for improved efficacy and safety compared to existing treatments.
Total Addressable Market (TAM)
The TAM for autoimmune and inflammatory disease therapies is estimated to be in the tens of billions of dollars annually. Equillium is targeting specific segments within this market, such as aGVHD and lupus nephritis, representing a multi-billion dollar opportunity. Their market share is currently 0 but hoping to capture a significant portion if approved.
Upturn SWOT Analysis
Strengths
- Novel immunomodulatory approach
- Potential for improved efficacy and safety
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Clinical-stage company with no approved products
- Reliance on itolizumab as lead product
- Significant competition in the autoimmune market
- High cash burn rate
Opportunities
- Successful clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
- Regulatory approvals
Threats
- Clinical trial failures
- Competition from established therapies
- Regulatory hurdles
- Patent challenges
- Economic recession
Competitors and Market Share
Key Competitors
- NVS
- RHHBY
- BMY
Competitive Landscape
Equillium faces significant competition from established pharmaceutical companies with approved therapies for autoimmune and inflammatory diseases. Their competitive advantage lies in the potential for itolizumab to offer improved efficacy and safety compared to existing treatments, but they still have to prove themselves.
Growth Trajectory and Initiatives
Historical Growth: Equillium's growth has been focused on advancing itolizumab through clinical development.
Future Projections: Future growth is dependent on the successful completion of clinical trials and regulatory approval of itolizumab. Analyst estimates vary widely, reflecting the uncertainty.
Recent Initiatives: Recent initiatives include progressing clinical trials for aGVHD and lupus nephritis, and exploring new indications for itolizumab.
Summary
Equillium is a clinical-stage biotech company with a promising lead product candidate, itolizumab. Success is heavily dependent on favorable clinical trial outcomes and regulatory approvals. Significant challenges are clinical-stage risks, competition, and financial stability. The company has a strong team and IP, but faces threats from larger, established players.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
- Yahoo Finance
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investing in biotech stocks carries significant risk. Market share estimates are based on available industry data and are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Equillium Inc
Exchange NASDAQ | Headquaters La Jolla, CA, United States | ||
IPO Launch date 2018-10-11 | Co-Founder, President, CEO & Director Mr. Bruce D. Steel C.F.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 35 | Website https://www.equilliumbio.com |
Full time employees 35 | Website https://www.equilliumbio.com | ||
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States. Its lead product candidate is Itolizumab (EQ001), a first-in-class anti-CD6 immune-modifying monoclonal antibody, which is in phase 3 clinical trial to treat acute graft-versus-host disease, as well as completed Phase 1b clinical trial to treat systemic lupus erythematosus and lupus nephritis and in phase 2 clinical trial for the treatment of ulcerative colitis. The company also develops EQ101, first-in-class, selective, tri-specific inhibitor of IL-2, IL-9 and IL-15, which completed Phase 1/2 to treat cutaneous T cell lymphoma. It serves its products to gastroenterology, dermatology, hematology, transplant science, rheumatology, pulmonology, and oncology areas. The company has a collaboration and license agreement with Biocon SA to develop, make, have made, use, sell, have sold, offer for sale, import and otherwise exploit itolizumab (EQ001) and any pharmaceutical composition or preparation containing or comprising itolizumab (EQ001) that uses Biocon technology or Biocon know-how, or collectively, a Biocon Product. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.